Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 2771 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed554    
    Printed34    
    Emailed0    
    PDF Downloaded52    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 1999  |  Volume : 41  |  Issue : 3  |  Page : 249-253

Multicentric Efficacy Study of Centpropazine and Imipramine in Depressed Patients


1 Division of Clinical & Experimental Medicine, Central Drug Research Institute, Lucknow, India
2 Department of Psychiatry, K. G. Medical College, Lucknow, India
3 Department of Psychiatry, Seth G. S. Medical College, Mumbai, India
4 Department of Psychiatry, Govt. Medical College, Patiala, India
5 Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India

Correspondence Address:
J S Srivastava
Division of Clinical & Experimental Medicine, Central Drug Research Institute, Lucknow
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21455398

Rights and PermissionsRights and Permissions

Centpropazine is a new antidepressant with minimal anticholinergic effects in preclinical animal models. In this study centpropazine has been compared with imipramine in a double blind randomized multicentric study. A total of 159 patients of major depressive disorder (79 in centpropazine group and 80 in imipramine group) from four centres were included in this trial. Each patient was randomised to receive either centpropazine in a dose of 40 to 120 mg per day or imipramine in a dose of 50 to 150 mg per day for a period of six weeks. The antidepressant efficacy of centpropazine was comparable to imipramine but anticholinergic side effects were four times less than imipramine. This establishes centpropazine as an effective antidepressant with remarkably safer tolerability profile.



[PDF]*

        

Print this article         Email this article